Rapidly generated virus specific T (R-MVST) cells

N/A

Report date: 2022/12/29 12:33:22

Base Information

Drug NameRapidly generated virus specific T (R-MVST) cells
Drug Alias NameRapidly generated virus specific T (R-MVST) cellsRapidly generated virus specific T cellsR-MVST
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsBK Polyomavirus InfectionsImmunologic Deficiency SyndromesEpstein-Barr Virus Infections +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesColumbia University
China Registration ClassN/A

Develop Information

Active CompaniesColumbia University
Inactive CompaniesN/A
Active IndicationsBK Polyomavirus InfectionsImmunologic Deficiency SyndromesEpstein-Barr Virus Infections +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A